Why AI and Biotech are BFFs

FromI AM BIO

Start listening View podcast show

Why AI and Biotech are BFFs

FromI AM BIO

ratings:

Length:

22 minutes

Released:

Mar 14, 2023

Format:

Podcast episode

Description

The convergence of Artificial Intelligence (AI) and biotechnology has emerged as one of the most exciting and transformative areas of science. Researchers are developing new tools and technology that could bring about breakthroughs to revolutionize the fields of medicine and health care. In this episode, we talk with scientists who are using AI to unlock new possibilities in the search for novel drugs, cures, and treatments.

Released:

Mar 14, 2023

Format:

Podcast episode

Titles in the series (100)

Powerful stories of biotechnology breakthroughs, the people they help, and the global problems they solve. Hosted by BIO President & CEO Dr. Michelle McMurry-Heath.

Skip carousel

“Herd” Immunity (Redux): Biotech companies are working feverishly to develop antibody therapies to provide short-term protection against COVID-19. But what if the novel coronavirus mutates and outwits traditional monoclonal antibodies? Well, that’s where the super cows come in. Hosted by Jim Greenwood. by I AM BIO
36 min listen
Coronavirus Lung Treatment Could be Ready In Weeks: Regeneron’s rheumatoid arthritis drug shows promise to treat coronavirus-related lung syndrome and stop the inflammation that leads to death. The company also expects to test a preventative antibody shot in June. Hosted by Jim Greenwood. by I AM BIO
40 min listen
Biotech’s Finest Hour: As the world waits for biotechnology to deliver COVID-19 treatments and a vaccine, Ambassador Deborah Birx tells BIO’s scientists: “Expectations are high because you’ve delivered for us before and I know that you can deliver for us again.” BIO chairman Jeremy Levin, a biotech pioneer, explains how the industry will rise to meet this moment. Hosted by Jim Greenwood. by I AM BIO
53 min listen
First Dose: One day before 16-year-old Izzy Thorpe-Wall takes her first dose of Vertex’s stunning Cystic Fibrosis breakthrough, Thorpe and her mother, Clare, open up about their emotional journey and one brave girl’s determination to stay healthy long enough to meet this day of her dreams. Hosted by Jim Greenwood. by I AM BIO
43 min listen
Superbuggin’: Incurable gonorrhea and the deadly hospital superbug C. diff offer a frightening window into the gathering public health menace of antibiotic resistance. If society doesn’t wake up and tackle the problem, we could be headed toward a calamity on the magnitude of climate change. Hosted by Jim Greenwood. by I AM BIO
28 min listen
COVID X-FACTOR: The diversity of our adaptive immune system is why people are reacting so differently to the novel coronavirus. No two people present the virus the exact same way to their immune systems. We’ve evolved in this way as humans to ensure no virus can eradicate our species. Hosted by Jim Greenwood. by I AM BIO
32 min listen
Vaccines are a Virtue: As biotech researchers work around the clock on a covid vaccine, ill-informed, anti-science anti-vaxxers must be denounced and excoriated in the public square. BIO’s head of infectious disease policy Phyllis Arthur administers a vital dose of vaccine education, because none of us is safe until we all are. Hosted by Jim Greenwood. by I AM BIO
33 min listen
Trying our Patients: As genetic sequencing gives scientists new tools to hone in on medical mysteries, Washington politicians flirt dangerously with policies that would stymie the genomic revolution while giving patients scant pricing relief at the pharmacy counter. Hosted by Jim Greenwood. by I AM BIO
36 min listen
The Antibody Test Shortage: Only antibody testing can tell us who has been infected and recovered from coronavirus and when it might be safe to return to work. There’s a massive global shortage of these tests, and a Maryland biotech is racing to bolster the U.S. supply. Hosted by Jim Greenwood. by I AM BIO
27 min listen
A Nation Traumatized: The pandemic has unleashed overwhelming levels of fear, isolation, anxiety and loss in our society. A CDC mental health survey this summer found that 1 in 10 people had “seriously considered” suicide within the last month. As America comes to grips with the severity of our ongoing mental health crisis, telepsychiatry has emerged as a virtual lifeline to help patients access treatment from home. by I AM BIO
28 min listen
COVID-19 Could Generate 1st Computerized Vaccine: Futuristic biotech Moderna is the first to clinically test a coronavirus vaccine, created in weeks using only the virus’ genetic code. The company’s messenger RNA breakthrough may be just in time as a former CDC director warns that animal viruses spilling over to humans is the new normal. Hosted by Jim Greenwood. by I AM BIO
60 min listen
An Alternative to Flying Dirty: While Swedish climate activist Greta Thunberg has kindled a global dialogue about the ravages of climate change and the role of airline emissions, a Colorado biotech is putting forward a jaw-dropping alternative to flight shaming: actual jet fuel with no carbon footprint. Hosted by Jim Greenwood. by I AM BIO
40 min listen
Sickle Cell Saviors: Need a dose of inspiration in a time of national tragedy? A remarkable biotech breakthrough from Global Blood Therapeutics offers fresh hope to patients living with sickle-cell disease. Hosted by Jim Greenwood. by I AM BIO
62 min listen
Going Viral: Vir Biotechnology CEO George Scangos is the scientist selected by his peers to lead the biotechnology industry’s efforts to mitigate and ultimately end the pandemic. He explains how and why the novel coronavirus is so contagious and potentially dangerous to millions. Hosted by Jim Greenwood. by I AM BIO
23 min listen
“Herd” Immunity: Biotech companies are working feverishly to develop antibody therapies to provide short-term protection against COVID-19. But what if the novel coronavirus mutates and outwits traditional monoclonal antibodies? Well, that’s where the super cows come in. Hosted by Jim Greenwood. by I AM BIO
36 min listen
COVID-19: We Were Warned: For years, leaders on the Bipartisan Commission on Biodefense told Congress and the White House that it wasn’t a matter of if, but when, a pandemic would happen. Exploring the panel’s unheeded recommendations can give the United States a blueprint for what to do going forward to protect us from the coronavirus and future threats. Hosted by Jim Greenwood. by I AM BIO
50 min listen
Destroying COVID's Genome: Alnylam Pharmaceuticals, which take its name from the center and brightest star in Orion’s Belt, is working on an RNAi therapy to destroy the genome of the novel coronavirus — and with it, its ability to replicate and kill. Hosted by Jim Greenwood. by I AM BIO
39 min listen
A Time to Heal: Joe Biden’s election as 46th President of the United States is a chance to soothe our bitter body politic so we can unite to defeat an enemy that infects and kills without regard to partisan affiliation. by I AM BIO
31 min listen
COVID-19’s True Origins (Redux): There's a joke among ecological health scientists that if “you don’t believe one person can change the world, try eating an undercooked bat.” However, what EcoHealth Alliance’s Dr. William Karesh — a world-renowned expert on zoonotic disease transmission — reveals about the trend line for animal-to-human viral transmission is no laughing matter. Hosted by Jim Greenwood. by I AM BIO
39 min listen
Deep Diving for COVID Cures: By studying our earliest evolutionary ancestors in the ocean, marine biotech researchers are gaining fresh insights about everything from anti-virals to coronavirus nasal swab testing to the inner workings of our adaptive immune systems. Learn what sea sponges, lugworms and sharks can teach us about improving human health during this crisis. Hosted by Jim Greenwood. by I AM BIO
43 min listen
What Can Iceland Tell Us About COVID?: The people of Iceland — a country of 360,000 — eagerly volunteered for genetic research on how the coronavirus affects a homogeneous population. Amgen’s work in the Land of Fire and here at home could deliver answers and antibodies to help mitigate the pandemic threat. Hosted by Jim Greenwood. by I AM BIO
32 min listen
Vaccine Velocity: How can global nonprofits like the Center for Epidemic Preparedness Innovations (CEPI) deliver a safe and effective vaccine against the novel coronavirus in just 12 to 18 months when the world record for vaccine approval is four years? CEPI CEO Richard Hatchett, a 9/11 hero, says it’s all about smart planning. By the time governments give the green light on the safety and efficacy of a covid vaccine, manufacturer capacity will be pre-scaled up and able to quickly churn out doses by the tens or hundreds of millions. Hosted by Jim Greenwood. by I AM BIO
33 min listen
Clinical Trials and Tribulations: As Moderna breaks the record for speed in starting the final stage of human testing for its covid vaccine, new BIO CEO Dr. Michelle McMurry-Heath tackles the thorny issue of how to best structure the historic Phase 3 clinical trial. The Boston biotech’s Chief Medical Officer reveals the strategy to test vaccine efficacy on communities of color and others hardest hit by the coronavirus. Hosted by Dr. Michelle McMurry-Heath by I AM BIO
29 min listen
COVID-19’s True Origins: There's a joke among ecological health scientists that if “you don’t believe one person can change the world, try eating an undercooked bat.” However, what EcoHealth Alliance’s Dr. William Karesh — a world-renowned expert on zoonotic disease transmission — reveals about the trend line for animal-to-human viral transmission is no laughing matter. Hosted by Jim Greenwood. by I AM BIO
39 min listen
The Other Pandemic: Beating “Nightmare Bugs” (Part 2 of 2): Viral pandemics can lead to secondary bacterial infections that kill millions, Dr. Anthony Fauci concluded after studying the 1918 Spanish flu. A century later, COVID and antibiotic resistance are proving to be a lethal combination. What are the biopharma industry and Congress doing to keep your loved ones safe from superbugs? Hosted by Jim Greenwood. by I AM BIO
32 min listen
Hydroxychloroquine & the Shorting of Science: Patients with autoimmune diseases like lupus and rheumatoid arthritis have been forced to ration or skip doses of hydroxychloroquine during the pandemic due to shortages caused by off-label prescribing. Yet despite multiple FDA clinical studies that concluded the drug offers no clinical benefit against covid and may increase dangerous side effects; President Trump continues to use the bully pulpit to suggest otherwise. It's not like autoimmune patients — at greater risk of serious COVID disease, stress-induced flare-ups and vaccine complications — didn’t have enough to worry about already. by I AM BIO
31 min listen
Biotech's Finest Hour (Redux): As the world waits for biotechnology to deliver COVID-19 treatments and a vaccine, Ambassador Deborah Birx tells BIO’s scientists: “Expectations are high because you’ve delivered for us before and I know that you can deliver for us again.” BIO chairman Jeremy Levin, a biotech pioneer, explains how the industry will rise to meet this moment. Hosted by Jim Greenwood. by I AM BIO
48 min listen
COVID’s Essential Work: The physician-wife of Roivant Sciences CEO Vivek Ramaswamy rushed back to the front lines at the pandemic’s peak — less than a month after giving birth to the couple’s first son. Meanwhile, dad cared for their newborn while testing a promising therapeutic that seeks to overcome deadly cytokine storms caused by the novel coronavirus. Hosted by Jim Greenwood. by I AM BIO
30 min listen
New Trailer with Dr. Michelle: The I AM BIO podcast with host Dr. Michelle McMurry-Heath explores the search for biotechnology breakthroughs and our progress in ending the pandemic, helping patients and carrying the mantle for science and sustainability. by I AM BIO
2 min listen
The Wrong Year to Skip Your Flu Shot: Two potentially deadly respiratory viruses — the coronavirus and the influenza virus — will test our health care system and American common sense this fall. As millions return to school, campus and work this fall, the 2020 flu season is shaping up to be something of a pandemic pressure test for our nation. Vaccinations, social distancing and mask-wearing will be the key to containing both flu and COVID and saving countless lives. Guest hosted by Phyllis Arthur. by I AM BIO
31 min listen

More Episodes from I AM BIO

Skip carousel

Editing Cells Within the Body—a New CRISPR Frontier: With its potential to expand the horizons of what’s possible for patients, CRISPR is the new darling of biotech. Reaching an important milestone in 2023 with the FDA approval of a sickle cell treatment using CRISPR, the technology is poised to break new barriers for treating patients in the near future. In this episode we talk with two companies working together on the next generation of CRISPR: editing cells within the body. We discuss the progress and the challenge in making this breakthrough a reality. by I AM BIO
21 min listen
Biotech is Climate Tech: Biotech companies are addressing climate change through innovation—from carbon neutral facilities to agricultural innovations to reduce greenhouse gas emissions. BIO was on the ground at the COP28 UN Climate Change Conference in Dubai to deliver the message that biotech is climate tech. by I AM BIO
21 min listen
Biotech for our Pets: More than half of U.S. households include pets, but there has been a lack of medical treatments developed specifically for small animals. Biotech companies are working to change that with new treatment options that both borrow from and, potentially, advance human health discoveries. by I AM BIO
28 min listen
What We Know About the Microbiome: The gut microbiome, which consists of trillions of bacteria, viruses, and fungi, plays a crucial role in our health. However, there is still much to learn about this complex ecosystem. On this episode we talk with experts who tell us where the science is—how much we know, and how much we don’t. Two companies, Bloom Science and Seres Therapeutics, are leveraging the microbiome to develop new therapeutics. The potential of the microbiome is vast, and further research and technological advancements will continue to unlock its benefits. by I AM BIO
27 min listen
Is CRISPR the New Sickle Cell Savior?: 2023 ended with an exciting biotech breakthrough for sickle cell patients. A gene-editing therapy using the revolutionary CRISPR technology provides new hope and options for the nearly 100,000 Americans with sickle cell disease. In this episode, we talk with the company behind one of the life-changing therapies, CASGEVY, and speak with two advocates for sickle cell patients. by I AM BIO
25 min listen
“On My Own”—Desperate to Stop a Resistant Bacterial Infection (REDUX): Bradley Burnam woke up one morning, looked in the mirror and found one ear twice it’s normal size and his face swollen and discolored. He would spend the next several years in and out of the hospital fighting a relentless infection that would not respond to available treatments. The experience took him from patient to mad scientist, to biotech company founder. In this episode, Bradley takes us through his desperate journey to find a cure. We also talk with the leader of an organization helping to get more antimicrobials to the marketplace. by I AM BIO
28 min listen
The Synbio Revolution is Here (REDUX): Innovative companies are using synthetic biology to engineer organisms and create new materials that could transform every sector of our economy, from health care to food and energy production. Those companies say we’ve entered a synbio revolution, and it holds potential to improve the health of people and our planet. In this episode, we talk with three synbio experts about how this convergence of genetic engineering, computer science and other scientific disciplines is making our world more sustainable. by I AM BIO
26 min listen
How Biotechs Survive the Valley of Death (REDUX): For biotech companies, the valley of death describes the difficult path from initial discovery to FDA approval and commercialization. It's a treacherous journey—one that even promising innovations often don't complete. Adequate funding, regulatory hurdles and the immense complexity of the biotech landscape are among the never-ending challenges faced by early stage biotechs. In this episode we talk with two biotech executives about what it’s like to struggle and survive in this rough-and-tumble industry. by I AM BIO
25 min listen
Biotech Women Striking at the Glass Ceiling (REDUX): The biotech industry offers unique opportunities for women to advance as executives and entrepreneurs. There are headwinds, however, including unequal access to venture capital. In this episode, we talk with three executives who are part of a wave of women-led companies in biotech. Our guests speak to why women’s leadership matters and the barriers that remain to breaking the glass ceiling. They also tell us about a new networking initiative—the biotech sisterhood—to catalyze women’s success in corporate leadership and mentor the next generation of women executives. by I AM BIO
25 min listen
We Need Bees. Bees Need Biotech. (REDUX): Bees and other pollinators are critical to our survival, with one out of every three bites of food we eat depending on pollination to produce. That’s why reports of a decline in bee populations and rising threats from pests, viruses and environmental pressures, including climate change, are alarming. In this episode we talk with an expert on bees and other pollinators about how bees are doing and why it’s important to save them. We also talk with two biotech leaders whose companies are working to improve bee health through development of innovative treatments for some of the worst threats faced by bees. by I AM BIO
27 min listen
The Horseshoe Crab Saved Us. Can We Save the Horseshoe Crab? (REDUX): The horseshoe crab has endured for over 450 million years. It has survived several mass extinctions including the one that killed off the dinosaurs. One reason for their incredible resiliency is their ability to fend off bacterial infection. Their blood contains cells that clot around invading bacteria, thereby protecting them from the attacking toxins. In this episode we talk with three experts about how this animal’s unique blue blood has become essential to modern medicine. We also talk about why horseshoe crab populations are dwindling, and what biotech is doing to address the shortfall. by I AM BIO
28 min listen
“On My Own”—Desperate to Stop a Resistant Bacterial Infection: Bradley Burnam woke up one morning, looked in the mirror and found one ear twice it’s normal size and his face swollen and discolored. He would spend the next several years in and out of the hospital fighting a relentless infection that would not respond to available treatments. The experience took him from patient to mad scientist, to biotech company founder. In this episode, Bradley takes us through his desperate journey to find a cure. We also talk with the leader of an organization helping to get more antimicrobials to the marketplace. by I AM BIO
28 min listen
The Synbio Revolution is Here: Innovative companies are using synthetic biology to engineer organisms and create new materials that could transform every sector of our economy, from health care to food and energy production. Those companies say we’ve entered a synbio revolution, and it holds potential to improve the health of people and our planet. In this episode, we talk with three synbio experts about how this convergence of genetic engineering, computer science and other scientific disciplines is making our world more sustainable. by I AM BIO
26 min listen
How Biotechs Survive the Valley of Death: For biotech companies, the valley of death describes the difficult path from initial discovery to FDA approval and commercialization. It's a treacherous journey—one that even promising innovations often don't complete. Adequate funding, regulatory hurdles and the immense complexity of the biotech landscape are among the never-ending challenges faced by early stage biotechs. In this episode we talk with two biotech executives about what it’s like to struggle and survive in this rough-and-tumble industry. by I AM BIO
25 min listen
Biotech Women Striking at the Glass Ceiling: The biotech industry offers unique opportunities for women to advance as executives and entrepreneurs. There are headwinds, however, including unequal access to venture capital. In this episode, we talk with three executives who are part of a wave of women-led companies in biotech. Our guests speak to why women’s leadership matters and the barriers that remain to breaking the glass ceiling. They also tell us about a new networking initiative—the biotech sisterhood—to catalyze women’s success in corporate leadership and mentor the next generation of women executives. by I AM BIO
25 min listen
We Need Bees. Bees Need Biotech.: Bees and other pollinators are critical to our survival, with one out of every three bites of food we eat depending on pollination to produce. That’s why reports of a decline in bee populations and rising threats from pests, viruses and environmental pressures, including climate change, are alarming. In this episode we talk with an expert on bees and other pollinators about how bees are doing and why it’s important to save them. We also talk with two biotech leaders whose companies are working to improve bee health through development of innovative treatments for some of the worst threats faced by bees. by I AM BIO
27 min listen
The Horseshoe Crab Saved Us. Can We Save the Horseshoe Crab?: The horseshoe crab has endured for over 450 million years. It has survived several mass extinctions including the one that killed off the dinosaurs. One reason for their incredible resiliency is their ability to fend off bacterial infection. Their blood contains cells that clot around invading bacteria, thereby protecting them from the attacking toxins. In this episode we talk with three experts about how this animal’s unique blue blood has become essential to modern medicine. We also talk about why horseshoe crab populations are dwindling, and what biotech is doing to address the shortfall. by I AM BIO
28 min listen
Stand Up for Science—The Fight Against Misinformation (Redux): Wading through the torrent of information available online is challenging for everyone. It can be hard to know what and whom to believe. We talk with the FDA Commissioner and other leaders on the frontlines of health and science about how to be more aware of false and misleading information, and its risks to our wellbeing and future innovation. And we discuss ways to stand up for science and stop the spread of misinformation. by I AM BIO
26 min listen
Is Space the Next Frontier for Biotech? (Redux): The International Space Station has been orbiting in lower earth since 1998 and has been continually inhabited since November 2000. The ISS was originally conceived as a staging base for future missions into deep space. As it turns out, lower earth orbit is an ideal setting for scientific research, from physics and meteorology to astronomy and the life sciences. In this episode we talk with three scientists whose projects are using lower earth orbit to deepen our knowledge of biotechnology and its benefits for mankind. by I AM BIO
27 min listen
The New Age of CRISPR (Redux): CRISPR has emerged as a powerful tool for altering DNA sequences with incredible precision, opening up new avenues of research into the treatment of disease. In this episode, we explore the science behind CRISPR, as well as its potential. From curing genetic disorders to creating new crop varieties, the possibilities seem endless. Our four guests today are scientists working to push these gene editing tools to the next frontier. by I AM BIO
28 min listen
Accelerating Hope: The Pathway for Cures (Redux): When people were dying from AIDS in the 1980s and 90s, Congress found a way to expedite the drug approval process and saved countless lives. Established in 1992, the Accelerated Approval Program allows the FDA to speed approval of drugs for patients with serious and life-threatening conditions. In this episode we talk with the father of children with a rare disease, a company CEO working to treat rare diseases and two policy experts on Accelerated Approval. by I AM BIO
23 min listen
Why AI and Biotech are BFFs (Redux): The convergence of Artificial Intelligence (AI) and biotechnology has emerged as one of the most exciting and transformative areas of science. Researchers are developing new tools and technology that could bring about breakthroughs to revolutionize the fields of medicine and health care. In this episode, we talk with scientists who are using AI to unlock new possibilities in the search for novel drugs, cures, and treatments. by I AM BIO
22 min listen
Cracking the Code on Pain Relief (Redux): Imagine living with excruciating pain that prevents you from walking or doing the things most of us take for granted. We all experience pain, and 50 million people cope with chronic, debilitating pain. The market for pain therapies is estimated at $74 billion. And yet, investment in new pain and addiction treatments is falling short of what is needed, according to a new BIO report, which shows a 44% decrease in clinical drug programs for pain over the past five years. Our guests on this episode talk about the challenges of living with and treating pain, as well as research and development on new, non-addictive and safer pain therapies. by I AM BIO
26 min listen
Why are Katie Couric and 15K People Headed to Boston?: During the last several decades Boston has become a biotech Mecca, with its Kendall Square attracting more than 120 biotech companies, both large and small. It is called the most innovative square mile on the planet. This June BIO will bring over 15,000 biotech leaders to Boston for its 2023 BIO International Convention. Speakers including award-winning journalist and health advocate, Katie Couric, will talk about how they will “Stand up for Science”—the Convention’s theme. MassBIO CEO, Kendalle Burlin O’Connell joins host, Rachel King in a wide-ranging discussion about how Boston became the largest biotech hub in the world. by I AM BIO
16 min listen
Stand Up for Science—The Fight Against Misinformation: Wading through the torrent of information available online is challenging for everyone. It can be hard to know what and whom to believe. We talk with the FDA Commissioner and other leaders on the frontlines of health and science about how to be more aware of false and misleading information, and its risks to our wellbeing and future innovation. And we discuss ways to stand up for science and stop the spread of misinformation. by I AM BIO
26 min listen
Is Space the Next Frontier for Biotech?: The International Space Station has been orbiting in lower earth since 1998 and has been continually inhabited since November 2000. The ISS was originally conceived as a staging base for future missions into deep space. As it turns out, lower earth orbit is an ideal setting for scientific research, from physics and meteorology to astronomy and the life sciences. In this episode we talk with three scientists whose projects are using lower earth orbit to deepen our knowledge of biotechnology and its benefits for mankind. by I AM BIO
27 min listen
The New Age of CRISPR: CRISPR has emerged as a powerful tool for altering DNA sequences with incredible precision, opening up new avenues of research into the treatment of disease. In this episode, we explore the science behind CRISPR, as well as its potential. From curing genetic disorders to creating new crop varieties, the possibilities seem endless. Our four guests today are scientists working to push these gene editing tools to the next frontier. by I AM BIO
28 min listen
Accelerating Hope: The Pathway for Cures: When people were dying from AIDS in the 1980s and 90s, Congress found a way to expedite the drug approval process and saved countless lives. Established in 1992, the Accelerated Approval Program allows the FDA to speed approval of drugs for patients with serious and life-threatening conditions. In this episode we talk with the father of children with a rare disease, a company CEO working to treat rare diseases and two policy experts on Accelerated Approval. by I AM BIO
23 min listen
Cracking the Code on Pain Relief: Imagine living with excruciating pain that prevents you from walking or doing the things most of us take for granted. We all experience pain, and 50 million people cope with chronic, debilitating pain. The market for pain therapies is estimated at $74 billion. And yet, investment in new pain and addiction treatments is falling short of what is needed, according to a new BIO report, which shows a 44% decrease in clinical drug programs for pain over the past five years. Our guests on this episode talk about the challenges of living with and treating pain, as well as research and development on new, non-addictive and safer pain therapies. by I AM BIO
26 min listen
Psychedelics – Not Just For Hippies Anymore (Redux): Not that long ago psychedelics were considered dangerous, and only enjoyed recreationally by a fringe element of society. Today, researchers are looking at drugs like psilocybin to develop treatments for depression, PTSD, addiction, and anxiety. This episode features guests steeped in the world of psychedelics who are finding new ways to treat mental health. by I AM BIO
21 min listen

Related podcast episodes

Skip carousel

E36: How To Use AI To Know If Your Drug Is Optimally Priced: In this episode of AI For Pharma Growth, Dr Andree Bates is joined by Alan Crowther who leads the Navlin practice at the company Eversana. Eversana’s integrated platform combines data and artificial intelligence powered insights... by AI For Pharma Growth
35 min listen
Episode 180.0: Urine Tox Screens: We discuss the (F)utility(?) of ED Utox screens with our very own Dr. Phil DiSalvo. Hosts: Bree Tse, MD Brian Gilberti, MDRead More by Core EM - Emergency Medicine Podcast
20 min listen
025 - The Parenteral Drug Association & Evolution of Drug Development with Michael Carroll: Michael Carrol is Senior Consultant of Microbiology and Aseptic Manufacturing at Design Space InPharmatics. He is an accredited Microbiologist with over 35 years of product development, quality control and GMP manufacturing experience in the pharmaceutical, biotechnology and medical device industries. In this episode, Ed, Meranda, Brian and Mike discuss the Parenteral Drug Association, the role of regulatory approvals and other stories from Mike’s illustrious career. They talk about the ever-evolving nature of CMC and the pressures of working in drug development and manufacturing. by CMC Live - Chemistry, Manufacturing & Controls
32 min listen
In the trenches of pharma manufacturing: In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Ray Kaczmarek, Chief Executive Officer at Genezen. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply ch... by Molecule to Market: Inside the outsourcing space
55 min listen
Cost-effectiveness Analysis for Clinicians: Cost-effectiveness analysis defines trade-offs between costs, harms, and benefits of alternative treatments and combines them into a single metric, the incremental cost-effectiveness ratio (ICER), that can inform decisions about which interventions to... by JAMA Clinical Reviews
20 min listen
Biosimilars with Dr. Gary Lyman: Existing biosimilars are safe, effective alternatives to their reference biologics, and are increasingly being incorporated into oncology treatment guidelines. Technological advances that have emerged in the years since biologic agents entered the... by Blood & Cancer
32 min listen
How Will the Revised Annex 1 Impact Your Contamination Control Strategy by The Qualitalks Podcast
21 min listen
Make care at home the standard of care: During the pandemic, many health systems piloted hospital at home and remote patient monitoring programs. As more and more providers and patients have experienced the benefits of receiving advanced care in the comfort of their homes, adoption has... by Modern Healthcare’s Healthcare Insider Podcast
13 min listen
Medication Safety During Pregnancy: On this episode, we discuss medication safety during pregnancy. We start by listing common teratogens to watch for in patients that are currently pregnant or trying to become pregnant. We then review the preferred treatment options for common disease... by CorConsult Rx: Evidence-Based Medicine and Pharmacy
48 min listen
Complexity in Early Phase Clinical Trials with Dr. Oren Cohen: When a new drug or device undergoes “first in human” experience, the primary focus is on participant safety. How will the drug or device interact with the human body? And will this interaction be safe? To answer these two questions,... by Clinical Trial Podcast | Conversations with Clinical Research Experts
80 min listen
FDA Regulation and Approval of Medical Devices: Rules for the regulation of medical devices, such as hip prostheses and implantable defibrillators, are complex and differ from those for drugs. Aaron Kesselheim, MD, JD, MPH, and Jonathan Darrow, SJD, LLM, JD, MBA, both faculty members in the... by JAMA Clinical Reviews
34 min listen
How Drug Companies Keep Prices High: We examine the tactics used by the drug companies to keep medicine prices high. by 5 Live Investigates
48 min listen
Why You Age And What To Do About It: In order to know how to reverse our skin’s aging, we need to know what actually causes it. In this podcast, I go in detail about why our skin ages, including explaining collagen degradation, oxidation, and autophagy. I also explain steps you can... by Holistic Plastic Surgery Show
29 min listen
How does EU MDR impact your Quality Management System?: <p><span style="color: rgb(0, 0, 0); background-color: transparent;">The new medical device regulation in the European Union (EU MDR) has introduced a host of new challenges for medical device companies. One challenge, in particular, has to do with the... by Global Medical Device Podcast powered by Greenlight Guru
36 min listen
005 Pharmaceutical Regulations in CMC - Dr. Catherine Bernard: DS InPharmatics Senior Regulatory Affairs Consultant, Dr. Catherine Bernard joins the show to share her experience in regulatory affairs in the pharmaceutical industry and preparing dossiers associated with CMC. In this episode, Ed, Brian, Meranda and Catherine discuss breakthrough designations, the role of agencies such as the FDA, and future trends in pharmaceutical regulation. by CMC Live - Chemistry, Manufacturing & Controls
35 min listen
Risk Management for Clinical Investigators with Bijan Elahi: This is a special episode on risk management. It is important to understand what dictates the work we do as clinical research professionals and how our work fits into the bigger picture of medical product development. This episode serves exactly that... by Clinical Trial Podcast | Conversations with Clinical Research Experts
65 min listen
Why AI and Biotech are BFFs (Redux): The convergence of Artificial Intelligence (AI) and biotechnology has emerged as one of the most exciting and transformative areas of science. Researchers are developing new tools and technology that could bring about breakthroughs to revolutionize the fields of medicine and health care. In this episode, we talk with scientists who are using AI to unlock new possibilities in the search for novel drugs, cures, and treatments. by I AM BIO
22 min listen
Will AI Replace Doctors? Concerned Doctor Speaks Out - Dr. Michael Ash by The Wellness Way
60 min listen
Part 3 – AI in the Lab: Accelerating Antibiotic Discovery: Artificial intelligence has the power to transform the way researchers study bacteria and develop new treatments – and we’re already seeing the benefits in healthcare. In part three, host Jeremiah Owyang and expert guests shed light on how AI expedites and enhances analyses, revolutionizing the search for new antibiotics. The benefits of AI extend to analyzing bacterial DNA, uncovering vulnerabilities, and potentially predicting bacterial evolution. This innovative technology aids scientists in pinpointing the most promising antibiotic candidates from a sea of possibilities and helps to streamline drug development. by Science Will Win
27 min listen
Eben Kirksey, "The Mutant Project: Inside the Global Race to Genetically Modify Humans" (St. Martin's Press, 2020): An interview with Eben Kirksey by New Books in Science
62 min listen
Stuart Ritchie, "Science Fictions: Exposing Fraud, Bias, Negligence, and Hype in Science" (Penguin Books, 2020): Scientists seek the truth, and we rely on them. Should we? by New Books in Psychology
78 min listen
Stuart Ritchie, "Science Fictions: Exposing Fraud, Bias, Negligence, and Hype in Science" (Penguin Books, 2020): Scientists seek the truth, and we rely on them. Should we? by New Books in Science
78 min listen
Eben Kirksey, "The Mutant Project: Inside the Global Race to Genetically Modify Humans" (St. Martin's Press, 2020): An interview with Eben Kirksey by New Books in Disability Studies
62 min listen
The Synbio Revolution is Here: Innovative companies are using synthetic biology to engineer organisms and create new materials that could transform every sector of our economy, from health care to food and energy production. Those companies say we’ve entered a synbio revolution, and it holds potential to improve the health of people and our planet. In this episode, we talk with three synbio experts about how this convergence of genetic engineering, computer science and other scientific disciplines is making our world more sustainable. by I AM BIO
26 min listen
The Synbio Revolution is Here (REDUX): Innovative companies are using synthetic biology to engineer organisms and create new materials that could transform every sector of our economy, from health care to food and energy production. Those companies say we’ve entered a synbio revolution, and it holds potential to improve the health of people and our planet. In this episode, we talk with three synbio experts about how this convergence of genetic engineering, computer science and other scientific disciplines is making our world more sustainable. by I AM BIO
26 min listen
Can AI make healthcare human again? with Eric Topol: Eric Topol is a leading health expert whose writing and explainers about Covid-19 have helped people better understand the complexities of the global pandemic. by The TED Interview
46 min listen
Impact Series: Solving Medical Mysteries with Aperiomics: The BioScience Talks Impact Series focuses on the path from newly gained scientific knowledge to real-world effects, addressing questions such as How does a new vaccine find its way to physicians' offices? How do ecological discoveries result in new natu by BioScience Talks
30 min listen
From Single Neurons to AI Systems: The Evolution of Decision Sciences in Medicine with Dr. Eric Horvitz: In this episode of the AI Grand Rounds podcast, Dr. Eric Horvitz describes his career evolution from an interest in neurobiology to significant contributions in AI, particularly in understanding complex systems and applying AI in medicine. He discuss... by NEJM AI Grand Rounds
68 min listen
The Future of AI in Healthcare with Matt Lewis from Inizio Health by AI Applied: Covering AI News, Interviews and Tools - ChatGPT, Midjourney, Gemini, OpenAI, Anthropic
27 min listen
Life Science Trends for 2024 by Xtalks Life Science Podcast
43 min listen

Discover this podcast and so much more

Why AI and Biotech are BFFs

Why AI and Biotech are BFFs

Description

Titles in the series (100)

More Episodes from I AM BIO

Related podcast episodes